Latest news
Debiopharm Underlines Commitment to Eradicating Antimicrobial Resistance by Sponsoring the 8th Annual World AMR Conference
Debiopharm joins discussions with international health organisations to fight anti-microbial resistance at the 2023 World AMR Congress
One drug for one bug: Debiopharm to discuss the potential of pathogen-specific antibiotics at the 2022 World AMR Congress
Debiopharm International SA Initiates a Clinical Trial Phase II study evaluating afabicin in Bone and Joint Infections
Debiopharm International SA Announces positive Phase 2 Clinical Trial with Debio 1450 in ABSSSI patients
Debiopharm International SA Reaches Important Development Milestones for its Staphylococcus-selective antibiotic Debio 1450
Debiopharm International SA to present the latest findings on Debio 1450 at ECCMID
Debiopharm International SA initiates clinical phase II study evaluating Debio 1450 in Staphylococcal skin infections
FDA Grants Fast Track designation to Debiopharm Group’s antibiotic Debio 1450